Hearing on “Priced Out of a Lifesaving Drug: Getting Answers on the Rising Cost of Insulin”
The Oversight and Investigations Subcommittee held a hearing on Wednesday, April 10, at 10:30 am in 2322 of the Rayburn House Office Building. The hearing is entitled, “Priced Out of a Lifesaving Drug: Getting Answers on the Rising Cost of Insulin.” This will be the second hearing on the rising cost of insulin.
Key Documents
Memorandum from Chairman Pallone to the Subcommittee on Oversight and Investigations
Opening Statement of Chairman Pallone as prepared for delivery
Opening Statement of Subcommittee Chair DeGette as prepared for delivery
Livestream
Witnesses
Mike Mason
Senior Vice President, Lilly Connected Care and Insulins Global Business Unit
Eli Lilly and Company
Doug Langa
Executive Vice President, North America Operations, and President of Novo Nordisk Inc.
Novo Nordisk
Kathleen Tregoning
Executive Vice President for External Affairs
Sanofi
Thomas Moriarty
Executive Vice President, Chief Policy and External Affairs Officer, and General Counsel
CVS Health
Amy Bricker
Senior Vice President, Supply Chain
Express Scripts
Sumit Dutta, MD
Senior Vice President and Chief Medical Officer
OptumRx